Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Radiology

22-04-2024 | Hamartoma | Original Article

Imaging findings of children with PTEN-related hamartoma tumor syndrome: a 20-year multicentric pediatric cohort

Authors: Claudia Martinez-Rios, Laura S. De Leon Benedetti, Luis Octavio Tierradentro-Garcia, Ozge Aksel Kilicarslan, Pablo Caro-Dominguez, Hansel J. Otero

Published in: Pediatric Radiology

Login to get access

Abstract

Background

PTEN-related hamartoma tumor syndrome results from a mutation in the PTEN gene located at 10q23.31. This syndrome represents a spectrum of different phenotypes of variable expressions, now recognized as part of the same condition. Patients with this mutation have an increased risk of developing a wide range of findings, including malignancies. Although widely described in adults, there are no large series describing the imaging findings in patients before adulthood. Knowledge of the findings seen in children and adolescents with PTEN-related hamartoma tumor syndrome can help guide further management and improve surveillance recommendations.

Objective

To describe the spectrum of imaging abnormalities in pediatric patients with PTEN-related hamartoma tumor syndrome.

Materials and methods

We performed a retrospective, cross-sectional, multicenter study conducted between January 2000 and October 2021 in three tertiary pediatric institutions evaluating the imaging findings in children and adolescents (≤ 18 years) with confirmed diagnoses of a PTEN mutation. For each patient, the imaging findings, histopathology reports, and at least a 2-year follow-up of clinical outcomes for non-operative cases were documented.

Results

The cohort included 78 children (37 girls), with a mean age at diagnosis of 7.5 years (range 0 days to 18 years). Benign brain findings included enlarged Virchow-Robin perivascular spaces, white matter changes, developmental venous anomalies, and cerebellar hamartomas. Benign thyroid findings were common, but 5/45 (11.1%) with thyroid abnormalities had a malignant nodule. Soft tissue adipocytic tumors, GI/GU polyps, other soft tissue abnormalities, along with vascular anomalies in various anatomic locations were common.

Conclusion

Brain abnormalities, benign non-vascular soft tissue abnormalities, and vascular anomalies are commonly seen in children and adolescents with PTEN-related hamartoma tumor syndrome. However, malignancies involving the thyroid gland are not uncommon. Familiarity with the phenotype of PTEN-related hamartoma tumor syndrome in the pediatric population can improve diagnosis and prompt appropriate clinical surveillance of abnormal findings that warrant further management.

Graphical abstract

Appendix
Available only for authorised users
Literature
1.
Hobert JA, Eng C (2009) PTEN hamartoma tumor syndrome: an overview. Genet Med Oct 11(10):687–694CrossRef
2.
Macken WL, Tischkowitz M, Lachlan KL (2019) PTEN Hamartoma tumor syndrome in childhood: a review of the clinical literature. Am J Med Genet C Semin Med Genet Dec 181(4):591–610CrossRef
3.
Yehia L, Eng C (2020) PTEN hamartoma tumour syndrome: what happens when there is no PTEN germline mutation? Hum Mol Genet Oct 20(R2):R150–R157CrossRef
4.
Ciaccio C, Saletti V, D’Arrigo S, Esposito S, Alfei E, Moroni I, Tonduti D, Chiapparini L, Pantaleoni C, Milani D (2019) Clinical spectrum of PTEN mutation in pediatric patients. A bicenter experience. Eur J Med Genet Dec 62(12):103596CrossRef
5.
Yehia L, Ngeow J, Eng C (2019) PTEN-opathies: from biological insights to evidence-based precision medicine. J Clin Invest Feb 1(2):452–464CrossRef
6.
Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR (2019) Mechanisms of PTEN loss in cancer: it’s all about diversity. Semin Cancer Biol Dec 59:66–79CrossRef
7.
Leslie NR, Longy M (2016) Inherited PTEN mutations and the prediction of phenotype. Semin Cell Dev Biol Apr 52:30–38CrossRef
8.
Zou Z, Tao T, Li H, Zhu X (2020) mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci Mar 10:10:31CrossRef
9.
Jonker LA, Lebbink CA, Jongmans MCJ, Nievelstein RAJ, Merks JHM, van Nieveen EJM, Links TP, Hoogerbrugge N, van Trotsenburg ASP, van Santen HM (2020) Recommendations on surveillance for differentiated thyroid carcinoma in children with PTEN hamartoma tumor syndrome. Eur Thyroid J Sep 9(5):234–242CrossRef
10.
Nasr Y, Bettoli M, El Demellawy D, Sekhon H, de Nanassy J (2019) Sclerosing pneumocytoma of the lungs arising in a child with PTEN mutation. Pediatr Dev Pathol Nov-Dec 22(6):579–583CrossRef
11.
Plamper M, Born M, Gohlke B, Schreiner F, Schulte S, Splittstößer V, Woelfle J (2020) Cerebral MRI and clinical findings in children with PTEN hamartoma tumor syndrome: can cerebral MRI scan help to establish an earlier diagnosis of PHTS in Children? Cells Jul 10(7):1668CrossRef
12.
Smpokou P, Fox VL, Tan WH (2015) PTEN hamartoma tumour syndrome: early tumour development in children. Arch Dis Child Jan 100(1):34–37CrossRef
13.
Tan MH, Mester JL, Ngeow J, Rybicki LA, Orloff MS, Eng C (2012) Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res Jan 15(2):400–407CrossRef
14.
Balci TB, Davila J, Lewis D, Boafo A, Sell E, Richer J, Nikkel SM, Armour CM, Tomiak E, Lines MA, Sawyer SL (2018) Broad spectrum of neuropsychiatric phenotypes associated with white matter disease in PTEN hamartoma tumor syndrome. Am J Med Genet B Neuropsychiatr Genet Jan 177(1):101–109CrossRef
15.
Dhamija R, Hoxworth JM (2020) Imaging of PTEN-related abnormalities in the central nervous system. Clin Imaging Apr 60(2):180–185CrossRef
16.
Lok C, Viseux V, Avril MF, Richard MA, Gondry-Jouet C, Deramond H, Desfossez-Tribout C, Courtade S, Delaunay M, Piette F, Legars D, Dreno B, Saïag P, Longy M, Lorette G, Laroche L, Caux F, Cancerology Group of the French Society of Dermatology (2005) Brain magnetic resonance imaging in patients with Cowden syndrome. Med (Baltimore) Mar 84(2):129–136CrossRef
17.
Vanderver A, Tonduti D, Kahn I, Schmidt J, Medne L, Vento J, Chapman KA, Lanpher B, Pearl P, Gropman A, Lourenco C, Bamforth JS, Sharpe C, Pineda M, Schallner J, Bodamer O, Orcesi S, Oberstein SA, Sistermans EA, Yntema HG, Bonnemann C, Waldman AT, van der Knaap MS (2014) Characteristic brain magnetic resonance imaging pattern in patients with macrocephaly and PTEN mutations. Am J Med Genet Mar 164A(3):627–633CrossRef
18.
Dragoo DD, Taher A, Wong VK, Elsaiey A, Consul N, Mahmoud HS, Mujtaba B, Stanietzky N, Elsayes KM (2021) PTEN Hamartoma Tumor Syndrome/Cowden Syndrome: Genomics, Oncogenesis, and Imaging Review for Associated Lesions and Malignancy. Cancers (Basel) Jun 22;13(13):3120
19.
Golpanian S, Perez EA, Tashiro J, Lew JI, Sola JE, Hogan AR (2016) Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. Pediatr Surg Int Mar 32(3):201–208CrossRef
20.
Baran JA, Tsai SD, Isaza A, Brodeur GM, MacFarland SP, Zelley K, Adams DM, Franco AT, Bauer AJ (2020) The clinical spectrum of PTEN hamartoma tumor syndrome: exploring the value of thyroid surveillance. Horm Res Paediatr 93(11–12):634–642CrossRefPubMed
21.
Tischkowitz M, Colas C, Pouwels S, Hoogerbrugge N, PHTS Guideline Development Group; European Reference Network GENTURIS (2020) Cancer Surveillance Guideline for individuals with PTEN hamartoma tumour syndrome. Eur J Hum Genet Oct 28(10):1387–1393CrossRef
22.
Plitt G, Brewer T, Yehia L, Jin J, Shin J, Eng C (2022) Development and progression of thyroid disease in PTEN hamartoma tumor syndrome: refined surveillance recommendations. Thyroid Sep 32(9):1094–1100CrossRef
23.
Guerra-Gutiérrez F, Torres Sánchez I, Gallardo-Madueño G, Mariño-Enríquez A, Nistal M (2007) Hemangioma Esclerosante pulmonar en un paciente con síndrome de Cowden [Pulmonary sclerosing hemangioma in a patient with Cowden syndrome]. Arch Bronconeumol Jul 43(7):418–420
24.
Yalcin B, Bekci TT, Kozacioglu S, Bolukbas O (2019) Pulmonary sclerosing pneumocytoma, a rare tumor of the lung. Respir Med Case Rep Feb 13:26:285–287
25.
Martin H, Bessis D, Bourrat E, Mazereeuw-Hautier J, Morice-Picard F, Balguerie X, Chiaverini C (2020) Cutaneous lipomas and macrocephaly as early signs of PTEN hamartoma tumor syndrome. Pediatr Dermatol Sep 37(5):839–843Groupe de Recherche de la Société Française de Dermatologie Pédiatrique
26.
Kurek KC, Howard E, Tennant LB, Upton J, Alomari AI, Burrows PE, Chalache K, Harris DJ, Trenor CC 3rd, Eng C, Fishman SJ, Mulliken JB, Perez-Atayde AR, Kozakewich HP (2012) PTEN hamartoma of soft tissue: a distinctive lesion in PTEN syndromes. Am J Surg Pathol May 36(5):671–687CrossRef
27.
Gurunathan A, Ricci K, Iacobas I, Rednam SP, Wusik K, Fei L, Hammilll AM (2020) Impact of vascular anomalies on the PTEN phenotype in children and young adults. Pediatr Blood Cancer Jun 67(6):e28258CrossRef
28.
Chism CB, Crawford L, Tchakarov A, Al-Ibraheemi A, Beckmann NM (2017) PTEN hamartoma of the soft tissue: the initial manifestation of an underlying PTEN hamartoma tumor syndrome in a 4-year-old female. Skeletal Radiol Nov 46(11):1591–1595CrossRef
29.
30.
Farooq A, Walker LJ, Bowling J, Audisio RA (2010) Cowden syndrome. Cancer Treat Rev Dec 36(8):577–583CrossRef
31.
Nelen MR, Kremer H, Konings IB, Schoute F, van Essen AJ, Koch R, Woods CG, Fryns JP, Hamel B, Hoefsloot LH, Peeters EA, Padberg GW (1999) Novel PTEN mutations in patients with Cowden disease: absence of clear genotype-phenotype correlations. Eur J Hum Genet Apr 7(3):267–273CrossRef
32.
33.
Plamper M, Gohlke B, Woelfle J (2022) PTEN hamartoma tumor syndrome in childhood and adolescence-a comprehensive review and presentation of the German pediatric guideline. Mol Cell Pediatr Feb 21;9(1):3
34.
Yehia L, Plitt G, Tushar AM, Joo J, Burke CA, Campbell SC, Heiden K, Jin J, Macaron C, Michener CM, Pederson HJ, Radhakrishnan K, Shin J, Tamburro J, Patil S, Eng C (2023) Longitudinal analysis of cancer risk in children and adults with germline PTEN variants. JAMA Netw Open Apr 36(4):e239705CrossRef
35.
Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R, National comprehensive cancer network (2014) Genetic/familial high-risk assessment: breast and ovarian, version 1.2014. J Natl Compr Canc Netw Sep 12(9):1326–1338CrossRef
Metadata
Title
Imaging findings of children with PTEN-related hamartoma tumor syndrome: a 20-year multicentric pediatric cohort
Authors
Claudia Martinez-Rios
Laura S. De Leon Benedetti
Luis Octavio Tierradentro-Garcia
Ozge Aksel Kilicarslan
Pablo Caro-Dominguez
Hansel J. Otero
Publication date
22-04-2024
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Radiology
Print ISSN: 0301-0449
Electronic ISSN: 1432-1998
DOI
https://doi.org/10.1007/s00247-024-05922-8